CLINICAL TRIALS PROFILE FOR ROZEREM
✉ Email this page to a colleague
505(b)(2) Clinical Trials for ROZEREM
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
OTC | NCT02840591 ↗ | Ramelteon and Citicoline for Delirium | Withdrawn | University of Texas Southwestern Medical Center | Phase 4 | 2016-07-01 | Primary aim of this study is to assess the feasibility of conducting clinical research for delirium (confusion due to medical problems) at Clements University Hospital in Dallas, Texas. A secondary aim is to assess whether an FDA-approved sleeping aid called Ramelteon or an over-the-counter supplement called Citicoline are safe and beneficial in delirium. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for ROZEREM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00237497 ↗ | Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia | Completed | Takeda | Phase 3 | 2005-07-01 | The purpose of the study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), compared to placebo with Zopiclone in adults with chronic insomnia |
NCT00247390 ↗ | Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. | Completed | Takeda | Phase 3 | 2005-07-01 | The purpose of this study to determine the long-term efficacy and safety of ramelteon, once daily (QD). |
NCT00316992 ↗ | Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease | Completed | Takeda | Phase 4 | 2006-04-01 | The purpose of this study is to determine if ramelteon has respiratory depressant effects in subjects with moderate to severe chronic obstructive pulmonary disease. |
NCT00325728 ↗ | Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease | Completed | Takeda | Phase 2 | 2006-03-21 | The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance |
NCT00337272 ↗ | Treating Chronic Insomnia in Breast Cancer Patients | Terminated | Takeda Pharmaceuticals North America, Inc. | Phase 4 | 2006-08-01 | This study is being conducted to evaluate the effectiveness of ramelteon 8mgs in the treatment of insomnia in patients that have completed their first chemotherapy treatment for breast cancer. |
NCT00337272 ↗ | Treating Chronic Insomnia in Breast Cancer Patients | Terminated | Accelerated Community Oncology Research Network | Phase 4 | 2006-08-01 | This study is being conducted to evaluate the effectiveness of ramelteon 8mgs in the treatment of insomnia in patients that have completed their first chemotherapy treatment for breast cancer. |
NCT00391755 ↗ | A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches | Terminated | Takeda Pharmaceuticals North America, Inc. | Phase 4 | 2006-10-01 | To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor agonist used for insomnia, as a migraine prophylactic agent. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROZEREM
Condition Name
Clinical Trial Locations for ROZEREM
Trials by Country
Clinical Trial Progress for ROZEREM
Clinical Trial Phase
Clinical Trial Sponsors for ROZEREM
Sponsor Name